Background {#S0001}
==========

Prostate cancer (PCa) incidence varies widely around the world, with by far the highest rates in North America and Oceania.[@CIT0001] In Germany, PCa is the most frequent cancer and the third leading cause of cancer death among men.[@CIT0002] In the USA, the implementation of prostate-specific antigen (PSA) testing for the early detection of PCa in 1986 resulted in a rapid increase in PCa incidence. In Germany and other European countries, PSA testing was implemented later and increased in the 1990s.[@CIT0003] Potentially caused by the introduction of the PSA testing, PCa incidence strongly increased during the following years in Germany, too.[@CIT0004],[@CIT0005] Risks and benefits of this PCa screening method are controversial. Diagnosis at earlier stage is one potential advantage of the PSA testing, while disadvantages such as overdiagnosis and -treatment of harmless tumors followed by possible complications, eg, incontinence and impotence, also have to be considered.[@CIT0006],[@CIT0007] Results of large studies such as the "European Randomized Study of Screening for Prostate Cancer" (ERSPC) and the "Prostate, Lung, Colorectal and Ovarian" (PLCO) trial show different findings. The ERSPC shows that the PCa mortality rates are possible to decrease by PSA testing, while in the PLCO trial they first concluded that screening was not associated with PCa mortality rates, whereas later results are in consistence with the ERSPC.[@CIT0008]--[@CIT0011] Study results and recommendations based on these studies influence PSA testing practice and also are essential for policy making.[@CIT0012]--[@CIT0014] In contrast to breast cancer early detection, PSA testing has not been approved as a PCa early detection service of the German statutory health insurance. Therefore, in Germany, PSA testing is an individual health service which has to be paid by the patient himself.

The 2014 version of the German S3 guideline on PCa was the first one with a "dissenting opinion" by the German College of General Practitioners and Family Physicians (Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin \[DEGAM\]) for the use of PSA testing in the field of general practice.[@CIT0015] Apart from differences in guidelines between countries and organizations, this guideline also states divergent recommendations for doctors working in different specialist disciplines, namely urology versus general practice. Urologists are advised to proactively inform men of at least 45 years of age and presumed life expectancy of at least 10 years of age about PSA testing, considering pros and cons. GPs should not actively inform men about PSA testing or only if the man asks for it. Therefore, it is expected that the daily routine in medical consultation, performance and other aspects concerning PSA testing varies. Despite the high significance of informed decision-making (for example emphasized in the German S3 guideline[@CIT0015]), the clinical experience also shows that there is big variation in practice. The way the patient is informed has a high impact on the patient's demand and use of medical services as well as on the satisfaction with early detection by PSA testing.[@CIT0016],[@CIT0017] A GP's recommendation clearly affects the patient's decision for or against a PSA test.[@CIT0018] Furthermore, insufficient knowledge or individual conviction of the doctor influences treatment decisions in practice.[@CIT0019],[@CIT0020] A survey among medical doctors with different specialties might highlight differences in PSA testing practice and in handling guidelines on PCa by specialist discipline.

This study was part of two affiliated pilot studies, aiming to assess attitude and practice of GPs and urologists on PSA testing. In this article, we focus on the survey based on the country-specific questionnaire covering the northwest of Lower Saxony and Bremen to investigate potential differences in daily routine practice regarding PSA testing between German GPs/internists and urologists.

Methods {#S0002}
=======

Study population {#S0002-S2001}
----------------

A survey was set up to assess potential differences in routine PSA practice. The survey covered GPs within the teaching network of the University of Oldenburg in Lower Saxony and Bremen and urologists approached by the registry of the Professional Association of German Urologists (Berufsverband der Deutschen Urologen \[BvDU\]). We only considered practicing urologists for our study. Overall, 172 GPs and 128 urologists were invited to participate in the online survey.

Questionnaire {#S0002-S2002}
-------------

The questionnaire covered 43 questions on several topics such as consultation, usage of the PSA test, processing of PSA test results, adherence to and knowledge about guidelines on PCa as well as characteristics of the respondents. Furthermore, the survey included four case scenarios to simulate situations and assess the GPs/urologist decision. The questionnaire was tested by three GPs and one urologist. The online questionnaire was developed using the software SoSci Survey ([www.soscisurvey.de](http://www.soscisurvey.de)).

Conducting the questionnaire {#S0002-S2003}
----------------------------

For conducting the questionnaire, the GPs and urologists first received an e-mail with information on the project and the upcoming questionnaire. A few weeks later (in June 2016), the survey started and the doctors received a link to the online questionnaire via e-mail. Three weeks later, the participants received a reminding e-mail. The interval for participation was about 7 weeks.

Statistical analysis {#S0002-S2004}
--------------------

Statistical analysis was done at descriptive level. We refer to the group urologists and the group GPs, where the latter also covers internists (n=5).

Results {#S0003}
=======

Response proportions and characteristics {#S0003-S2001}
----------------------------------------

Out of 172 GPs and 128 urologists, 64 participated overall, resulting in a response proportion of 21.3% (27.3%, n=47 \[GPs\]; 13.3%, n=17 \[urologists\]). Nine participants were excluded as they either did not finish the questionnaire (n=7) or were currently not working as a medical doctor (n=2). Unfortunately, no information is available for the nonparticipating physicians. Finally, the results of 55 questionnaires were considered for the analysis (see [Figure 1](#F0001){ref-type="fig"}). Group size differs between the two specialties (41 GPs and 14 urologists). Figure 1Flowchart of survey participants (general practitioners and urologists).**Abbreviation:** GPs, general practitioners.

[Tables 1](#T0001){ref-type="table"} and [2](#T0002){ref-type="table"} show the specialty and the characteristics of the respondents, respectively. The median age was 54.0 years for the GPs (IQR=10, mean=54.0, n=41) and 51.5 years for the urologists (IQR=8.75, mean=52.1, n=14). An unequal distribution was given for the sex of the respondents; there were no female urologists, while 87.8% (n=36) of the GPs were male (see [Table 2](#T0002){ref-type="table"}). Table 1Specialty of respondentsSpecialtyn%General medicine\
General medicine and internal medicine\
General medicine and surgery\
General medicine and anaestesia\
Internal medicine31\
2\
2\
1\
556.4\
3.6\
3.6\
1.8\
9.1Urology1425.5 Table 2Characteristics of respondents by general practitioners and urologists, n (%)VariableCategoriesGPsUrologists**Sex**Male36 (87.8)14 (100.0)Female4 (9.8)0 (0.0)Others1 (2.4)0 (0.0)**Specialty**Yes41 (100.0)14 (100.0)No0 (0.0)0 (0.0)**Type of practice**Solo12 (29.3)4 (28.6)Group23 (56.1)8 (57.1)Practice sharing5 (12.2)1 (7.1)Community health center1 (2.4)1 (7.1)[^1]

PSA testing practice {#S0003-S2002}
--------------------

Questions on PSA testing are provided in [Tables 3](#T0003){ref-type="table"}--[6](#T0006){ref-type="table"}. More than two-third of the GPs (65.9%, n=27) and nearly 90.0% of the urologists (85.7%, n=12) stated to follow a standard procedure regarding PSA testing which is not older than 3 years for the majority (63.0%, n=17 \[GPs\] and 58.3%, n=7 \[urologists\]). All urologists indicated that they inquire if the patient wishes to do a PSA test (majority of urologists \[85.7%, n=12\] orally). In the GP group, 24.4% (n=10) stated that they do not ask the patient if he wishes to do a PSA test, while 73.2% (n=30) do this orally (see [Table 3](#T0003){ref-type="table"}). Table 3Questions on PSA testing I by general practitioners and urologists, n (%)QuestionCategoriesGPsUrologists**Is there a standard procedure regarding PSA testing (in your practice)?**Yes27 (65.9)12 (85.7)No14 (34.1)2 (14.3)**If yes, how old is this standard?**≤3 years17 (63.0)7 (58.3)4--9 years6 (22.2)5 (41.7)≥10 years4 (14.8)0 (0.0)**Who is responsible for medical consultation on PSA testing (in your practice)?**Doctor11 (26.8)2 (14.3)Doctor, medical assistant3 (7.3)0 (0.0)No reply27 (65.9)12 (85.7)**How do you ask the patient if there is a wish to do a PSA test?**Not at all10 (24.4)0 (0.0)Oral30 (73.2)12 (85.7)Standardized written form0 (0.0)1 (7.1)Oral, standardized written form1 (2.4)1 (7.1)**How is the consultation on PSA testing done?**Oral33 (80.5)3 (21.4)Give away info material0 (0.0)1 (7.1)Oral, info material in waiting room1 (2.4)5 (35.7)Oral, give away info material7 (17.1)3 (21.4)Oral, info material in waiting room and give away0 (0.0)2 (14.3)Others namely...- Online decision aid PSA (of the AOK)1 (2.4)0 (0.0)- recommendations on info material regarding PSA testing1 (2.4)0 (0.0)- internet links1 (2.4)0 (0.0)[^2] Table 4Questions on PSA testing II by general practitioners and urologists, n (%)QuestionCategoriesGPsUrologistsNever + RarelySometimesAlways + OftenNever + RarelySometimesAlways + Often**On which occasions do you inform your patient on PSA testing?**Within an early cancer detection examination6 (14.6)4 (9.8)31 (75.6)0 (0.0)0 (0.0)14 (100.0)In case of a positive family anamnesis6 (14.7)4 (9.8)31 (75.7)0 (0.0)1 (7.1)13 (92.9)In case of discomfort in the lower urinary tract16 (39.1)8 (19.5)17 (41.5)1 (7.1)2 (14.3)11 (78.5)In case of unclear discomfort17 (41.5)10 (24.4)14 (34.2)1 (7.1)3 (21.4)10 (71.4)**How often do you discuss the following aspects with your patients before performing a PSA test?**Impact on overall mortality14 (34.2)4 (9.8)23 (56.1)2 (14.2)3 (21.4)9 (64.3)Impact on disease-specific mortality7 (17.1)3 (7.3)31 (75.6)2 (14.2)1 (7.1)11 (78.6)Impact on risk of metastasis9 (22.0)8 (19.5)24 (58.6)1 (7.1)1 (7.1)12 (85.7)Potential overdiagnosis3 (7.3)5 (12.2)33 (80.5)2 (14.2)1 (7.1)11 (78.6)Issue of false positives0 (0.0)6 (14.6)35 (85.4)0.0 (0)0 (0.0)14 (100.0)Potential anxiety during waiting on test result13 (31.7)6 (14.6)22 (53.7)6 (42.9)1 (7.1)7 (50.0)Potential follow-up examinations if the test result is conspicuous1 (2.4)8 (19.5)32 (78.0)0 (0.0)1 (7.1)13 (92.8)Adverse effects of the treatment5 (12.2)12 (29.3)24 (58.5)0 (0.0)6 (42.9)8 (57.1)[^3] Table 5Questions on PSA testing III, n (%)QuestionCategoriesGPsUrologists**When do you usually perform a PSA test if a patient asks for it?**Same day15 (36.6)8 (57.1)New appointment9 (22.0)0 (0.0)Depends on the patient14 (34.1)6 (42.9)Others, namely...0 (0.0)- after informing about benefit and risk1 (2.4)\-- test is only performed in justified exceptional cases1 (2.4)\-- sex, cycle1 (2.4)-**Which proportion of men aged 45 years and older in your practice finally receives (at least) one PSA test (irrespective of where the test is performed)?**Almost none7 (17.1)0 (0.0)Considerably less than half15 (36.6)0 (0.0)Approximately half8 (19.5)3 (21.4)Considerably more than half7 (17.1)8 (57.1)Almost all4 (9.8)3 (21.4)**Where is the blood sample (of the PSA test) analyzed?**In own practice1 (2.4)7 (50.0)External laboratory40 (97.6)6 (42.9)Others (eg, at a community health center)0 (0.0)1 (7.1)**How many years of life expectancy does an asymptomatic patient need to have at least for you to recommend a PSA test?**Irrespective of the life expectancy (meaning also for patients with life expectancy of \<5 years)6 (14.6)2 (14.3)5--9 years5 (12.2)4 (28.6)10--14 years10 (24.4)8 (57.1)≥ 15 years4 (9.8)0 (0.0)Not at all16 (39.0)0 (0.0)[^4] Table 6Questions on PSA testing IV, n (%)QuestionCategoriesGPsUrologists**Which further actions did you take the last time having an asymptomatic patient with an increased PSA level (according to your definition of increased)? Did you...**...check the PSA level within a certain interval?Yes22 (53.7)14 (100)No19 (46.3)0 (0.0)...directly refer the patient to a urologist? (only GPs' replies)Yes28 (68.3)n/aNo13 (31.7)n/aOthers, namelySonography1 (2.4)1 (7.1)Rectal examination and sonography1 (2.4)-Asked if the patient smokes1 (2.4)-Consultation and wait-and-see attitude1 (2.4)-PSA control after 6 months-1 (7.1)PSA control after antibiosis-1 (7.1)**Assuming you decided to check the PSA level again which, again, is conspicuous. How did you proceed with your last patient, again having an increased PSA level? Did you...**...perform a third PSA test?Yes3 (21.3)5 (35.7)No10 (76.9)9 (64.3)...directly refer the patient to a urologist? (only GPs' replies)Yes8 (61.5)n/aNo5 (38.5)n/aOther, namelyBiopsy-5 (35.5)Biopsy or MRI of the prostate-1 (7.1)Transrectal ultrasonography, if necessary biopsy-1 (7.1)Depending on the PSA level, if necessary biopsy-1 (7.1)Preclusion/treatment of infection-1 (7.1)[^5]

Three-fourths of the GPs and all urologists always or often inform men on PSA testing during an early detection of cancer examination (75.6%, n=31 \[GPs\]; 100.0%, n=14 \[urologists\]). In case of discomfort in the lower urinary tract and unclear discomfort, GPs replies indicated a heterogeneous picture, whereas urologists showed a more proactive approach of informing men on PSA testing. Similar results can be found for the frequency of discussing certain factors with men before testing. The majority of all respondents stated to always or often discuss the listed factors (see [Table 4](#T0004){ref-type="table"}). A more detailed table on the information communication of PSA testing can be found in [Table S1](#ST00013).

One-third of the GPs and a proportion of 50% of the urologists answered on when a test is performed if a patient asks for it, that they either test the same day (36.6%, n=15 \[GPs\]; 57.1%, n=8 \[urologists\]) or cannot give a generalized answer ("depends on the patient") (34.1%, n=14 \[GPs\]; 42.9%, n=6 \[urologists\]).

More than half of the GPs (53.7%, n=22) replied that the proportion of men aged 45 years and older that finally receives (at least) one PSA test (irrespective of where the test is performed) is almost none or considerably less than half. On the other hand, almost 80% of the urologists (78.5%, n=11) stated that almost all or considerably more than half finally receive (at least) one PSA test, while none of them chose almost none or considerably less than half. Almost all GPs indicated that the blood sample is analyzed in an external laboratory (97.6%, n=40), while half of the urologists (50.0%, n=7) conduct the analysis in their own practice. Although almost 40.0% of the GPs (39.0%, n=15) would not recommend a test at all, the majority of the urologists (57.1%, n=8) chose 10--14 years of life expectancy for an asymptomatic patient to recommend a PSA test (see [Table 5](#T0005){ref-type="table"}).

[Figure 2](#F0002){ref-type="fig"} shows the boxplots of the number of PSA tests performed during the last 2 weeks by GPs and urologists. As expected, the median number of tests performed by urologists is higher than the corresponding one of the GPs (27.5, n=41 and 2.0, n=14, respectively). Figure 2Number of PSA test performed during the last 2 weeks by general practitioners (n=41) and urologists (n=14).**Abbreviations:** GPs, general practitioners; PSA, prostate-specific antigen.

Being asked which further actions were taken the last time seeing an asymptomatic patient with an increased PSA level, more than half of the GPs (53.7%, n=22) indicated to have checked the PSA level within a certain interval, while 68.3% (n=28) directly referred the patient to a urologist (see [Table 6](#T0006){ref-type="table"}). All 14 urologists stated that they checked the PSA level within a certain interval the last time they saw an asymptomatic patient with an increased PSA level.

[Figure 3](#F0003){ref-type="fig"} shows the boxplots of the PSA level at which the participants would take further actions for an asymptomatic patient who received a PSA test within an early detection examination. For both groups the median was 4.0 (n=41 \[GPs\], n=14 \[urologists\]). Figure 3PSA level at which general practitioners (n=41) and urologists (n=14) would take further actions for an asymptomatic patient who received a PSA test within an early detection examination.**Abbreviations:** GPs, general practitioners; PSA, prostate-specific antigen.

Case scenarios {#S0003-S2003}
--------------

All urologists (100%, n=14) would recommend a PSA test to an asymptomatic patient without risk factors at a certain age. The corresponding figure for the GPs is 51.2% (n=21) (see [Table 7](#T0007){ref-type="table"}, case scenario 1). Following up on case scenario 1, the minimum age is illustrated in [Figure 4](#F0004){ref-type="fig"}. All urologists (100%, n=14) stated to actively address a PSA test to a 45-year old patient with at least 10 years of life expectancy who does not ask for an early detection examination based on PSA testing. This statement was given by less than half of the GPs (41.5%, n=17) (see [Table 7](#T0007){ref-type="table"}, case scenario 2). Almost one-third of the GPs (29.3%, n=12) would not recommend a second PSA test at all to a 45-year-old patient with a PSA level of 1--2 ng/mL (see [Table 7](#T0007){ref-type="table"}, case scenario 3). More than one-third of the GPs (39.1%, n=16) would never or rarely perform a PSA test in a patient older than 45 years having an obstructive voiding disorder. All urologists would at least sometimes perform a test in such a situation, whereas the majority (50.0%, n=7) stated often (see [Table 7](#T0007){ref-type="table"}, case scenario 4). Table 7Case scenarios, n (%)QuestionCategoriesGPsUrologists**Case scenario 1: Imagine you see an asymptomatic patient without risk factors. Would you recommend him a PSA test at a certain age?**Yes21 (51.2)14 (100.0)No19 (46.3)0 (0.0)Cannot reply to that question1 (2.4)0 (0.0)**Case scenario 2: Imagine you see a 45-year old patient with life expectancy of at least 10 years who does not ask for an early detection examination based on PSA testing in your practice. Would you actively address a PSA test?**Yes17 (41.5)14 (100.0)No24 (58.5)0 (0.0)**Case scenario 3: Imagine a 45-year old patient with life expectancy of at least 10 years, having a PSA level of 1--2ng/mL. Which interval would you recommend for a PSA test?**Interval every year or more often5 (12.2)5 (35.7)Interval every 2 years15 (36.6)6 (42.9)Interval every 3 years1 (2.4)2 (14.3)Interval every 4 years2 (4.9)1 (7.1)Interval less than every 4 years6 (14.6)0 (0.0)Not at all12 (29.3)0 (0.0)**Case scenario 4: How often do you perform a PSA test in a patient older than 45 years having an obstructive voiding disorder?**Never7 (17.1)0 (0.0)Rarely9 (22.0)0 (0.0)Sometimes13 (31.7)4 (28.6)Often8 (19.5)7 (50.0)Always4 (9.8)3 (21.4)[^6] Figure 4Case scenario 1a: Minimum age at which general practitioners (n=41) and urologists (n=14) would recommend a PSA test to an asymptomatic patient of a certain age without risk factors, if they would recommend one.**Abbreviation:** GPs, general practitioners.

[Figure 4](#F0004){ref-type="fig"} shows the boxplots of the minimum age at which GPs and urologists would recommend a PSA test to an asymptomatic patient of a certain age without risk factors. For both groups, the median was 45 years of age (n=41 \[GPs\], n=14 \[urologists\]).

Guidelines and recommendations {#S0003-S2004}
------------------------------

Knowledge about national/international guidelines and studies on PSA testing was related to the specialist discipline of the doctors. Most GPs indicated to be aware of and consider the practice recommendations on PSA screening of the German College of General Practice and Family Medicine,[@CIT0021] while all urologists indicated to know the German S3 guideline on PCa[@CIT0015] in detail (see [Table 8](#T0008){ref-type="table"}). Half of the GPs (48.8%, n=20) never heard about the European Association of Urology (EAU) guidelines on PCa.[@CIT0022] International recommendations and guidelines such as the American Urological Association (AUA) guidelines on PCa,[@CIT0023] the National Comprehensive Cancer Network (NCCN) guidelines on PCa early detection,[@CIT0024] the American Cancer Society (ACS) guidelines on PCa early detection[@CIT0025] and the recommendation statements of the US Preventive Services Task Force (USPSTF)[@CIT0026] were rarely known in detail. Further, they were less known among GPs than among urologists. The same picture was given for international studies such as the ERSPC and PLCO study.[@CIT0008]--[@CIT0011] More than half of the GPs (58.5%, n=24) pointed out that they have never heard about the ERSPC.Table 8Questions on guidelines and recommendations I by general practitioners and urologists I, n (%)QuestionCategoriesGPsUrologistsYes, I know it in detailYes, I heard about itNo, I never heard about itYes, I know it in detailYes, I heard about itNo, I never heard about it**Are you aware of the following guidelines and study recommendations/results regarding PSA testing (irrespective of the version)?**DEGAM recommendations21 (51.2)17 (41.5)3 (7.3)2 (14.3)9 (64.3)3 (21.4)German S3 guideline10 (24.4)28 (68.3)3 (7.3)14 (100.0)0 (0.0)0 (0.0)EAU guidelines3 (7.3)18 (43.9)20 (48.8)10 (71.4)4 (28.6)0 (0.0)AUA recommendations2 (4.9)9 (22.0)30 (73.2)3 (21.4)11 (78.6)0 (0.0)NCCN guidelines1 (2.4)7 (17.1)33 (80.5)1 (7.1)10 (71.4)3 (21.4)ACS guidelines1 (2.4)11 (26.8)29 (70.7)3 (21.4)7 (50.0)4 (28.6)USPSTF recommendations1 (2.4)7 (17.1)33 (80.5)4 (28.6)6 (42.9)4 (28.6)ERSPC2 (4.9)15 (36.6)24 (58.5)7 (50.0)5 (35.7)2 (14.3)PLCO2 (4.9)7 (17.1)32 (78.0)4 (28.6)5 (35.7)5 (35.7)[^7]

Urologists mostly consider the German S3 and the EAU guideline(s) in their daily practice, while GPs indicated a rather moderate consideration of the DEGAM recommendations (see [Table 9](#T0009){ref-type="table"}). None of the urologists and 5 (12.2%) of the GPs stated that their daily practice regarding PSA testing is less than moderately influenced by national/international studies and guidelines/recommendations (see [Table 10](#T0010){ref-type="table"}). Table 9Questions on guidelines and recommendations II by general practitioners and urologistsQuestionCategoriesGPsUrologistsMean (SD)Median1st Quartile3rd QuartilenMean (SD)Median1st Quartile3rd Quartilen**If yes (you are aware of the guidelines and study recommendations/results), do you consider them in your daily practice regarding PSA testing?**DEGAM recommendations56.6 (31.4)57.040.083.84011.8 (15.6)5.02.026.011German S3 guideline38.7 (28.9)37.513.357.04094.9 (7.7)96.091.8101.014EAU guidelines20.3 (22.5)7.02.046.02364.8 (35.9)73.526.5101.014AUA recommendations12.3 (16.0)5.01.020.01326.8 (28.5)20.51.847.514NCCNguidelines12.6 (17.7)4.51.019.81013.1 (12.3)6.01.027.011ACS guidelines14.5 (17.7)6.55.018.51421.3 (25.8)19.01.827.810USPSTF recommendations14.8 (18.8)8.51.821.51013.4 (12.6)12.51.024.310ERSPC14.7 (17.4)6.01.029.01942.8 (35.0)34.512.873.812PLCO14.9 (19.1)1.01.037.01110.8 (20.5)2.01.011.59[^8] Table 10Questions on guidelines and recommendations III by general practitioners and urologists, n (%)QuestionCategoriesGPsUrologists**To which extent do results of national and international studies and national and international guidelines/recommendations influence your daily practice regarding PSA testing?**Not at all2 (4.9)0 (0.0)Very weak2 (4.9)0 (0.0)Weak1 (2.4)0 (0.0)Moderate21 (51.2)2 (12.5)Strong11 (26.8)12 (85.7)Very strong4 (9.8)0 (0.0)[^9]

Comparing the results of the questionnaire to the content of the guidelines, it can be noticed that urologists as well as GPs partly did not treat men in consistence with the guidelines. For example, \>40% of the GPs (41.5%, n=17) would recommend a PSA test to an asymptomatic patient without risk factors, though both German guidelines stated for GPs not to recommend a PSA test to a patient described here (see [Table 7](#T0007){ref-type="table"}, case scenario 2).[@CIT0021], On the question which interval doctors would recommend for a PSA test, seeing a 45-year-old patient with a life expectancy of at least 10 years, having a PSA level of 1--2ng/mL, less than half of the doctors chose the right answer according to the German S3 guideline (interval every 2 years; 36.6%, n=15 \[GPs\]; 42.9%, n=6 \[urologists\]) (see [Table 7](#T0007){ref-type="table"}, case scenario 3).

Daily practice {#S0003-S2005}
--------------

More than 80% of both groups always examine digito rectally during an early cancer detection examination (80.5%, n=33 \[GPs\] and 85.7%, n=12 \[urologists\]). A rather heterogeneous result was observed for patients with a voiding order -- while all urologists (100%, n=14) always or often examine digito rectally, more than 40% of the GPs (41.5%, n=17) stated sometimes (see [Table 11](#T0011){ref-type="table"}).Table 11Questions on daily practice by general practitioners and urologists, n (%)QuestionCategoriesGPsUrologistsNever + RarelySometimesAlways + OftenNever + RarelySometimesAlways + Often**How often do you examine digito rectally in the following situations?**During an early cancer detection examination0 (0.0)4 (9.8)37 (90.3)0 (0.0)0 (0.0)14 (100.0)If there is blood in the patient´s stool0 (0.0)3 (7.3)38 (92.7)(0.0)0 (0.0)14 (100.0)If the patient has a voiding disorder4 (9.7)17 (41.5)20 (48.8)0 (0.0)0 (0.0)14 (100.0)If the patient is asymptomatic29 (70.3)8 (19.5)4 (9.8)0 (0.0)4 (28.6)10 (71.5)[^10]

PSA test and PCa risk {#S0003-S2006}
---------------------

The general opinion on the PSA test differed between the groups (see [Table 12](#T0012){ref-type="table"}). While two-third (64.3%, n=9) and one-third (35.7%, n=5) of the urologists judged the test as very useful and useful, respectively, the replies of the GPs were less homogeneous. More than one-third of the GPs (36.6%, n=15) judged the PSA test not to be useful. For a more detailed table on daily practice of digito rectal examining see [Table S2](#ST00014). Table 12Questions on PSA testing and prostate cancer risk, n (%)QuestionCategoriesGPsUrologists**How do you judge the PSA test in general?**Not useful at all6 (14.6)0 (0.0)Not useful9 (22.0)0 (0.0)Neither/nor4 (9.8)0 (0.0)Useful18 (43.9)5 (35.7)Very useful4 (9.8)9 (64.3)**Please state your opinion. Which of the following factors have an impact on the risk to develop PCa?**Higher age (45 years and older)41 (100.0)14 (100.0)Smoking24 (58.5)3 (21.4)Primary relative having PCa32 (78.0)13 (92.9)BPH5 (12.2)2 (14.3)Afro-American ethnicity2 (4.9)9 (64.3)**Did you ever discover a PCa in an asymptomatic patient younger than 60 years based on a PSA test that you performed?**Yes29 (70.7)14 (100.0)No12 (29.3)0 (0.0)**Did you ever undergo a PSA test? (only men replies)**Yes20 (55.6)14 (100.0)No16 (44.4)0 (0.0)[^11]

[Figure 5](#F0005){ref-type="fig"} shows the boxplots of the change in handling PSA testing during the last 10 years for GPs ( n=41) and urologists ( n=14). For the urologists, the median of 57.5 is slightly higher than the corresponding one of the GPs (53.0). Figure 5Change in handling PSA testing during the last 10 years for GPs (n=41) and urologists (n=14).**Abbreviations:** GPs, general practitioners; PSA, prostate-specific antigen.

[Figure 6](#F0006){ref-type="fig"} shows the boxplots of the score in agreement for undergoing a PSA test in the future for male GPs ( n=36) and male urologists ( n=14). The propensity to undergo a PSA test in the future is higher for urologists than for GPs (median 100.0 and 70.0, respectively). Figure 6Score in agreement for undergoing a PSA test in the future for male general practitioners (GPs) (n=36) and male urologists (n=14).**Abbreviations:**GPs, general practitioners; PSA, prostate-specific antigen.

The boxplots of the scores of GPs ( n=41) and urologists ( n=14) on the question if they think that the reduction of PCa-related mortality by early detection based on PSA testing is proven are shown in [Figure 7](#F0007){ref-type="fig"}. The median score for the urologists is more than five times higher than the corresponding one for the GPs (19.0 and 100.5, respectively). Figure 7Scores of GPs (n=41) and urologists (n=14) on the question if they think that the reduction of PCa-related mortality by early detection based on PSA testing is proven.**Abbreviations:** GPs, general practitioners; PSA, prostate-specific antigen..

Discussion {#S0004}
==========

This study aimed to give a first insight into the daily practice of PSA testing and potential differences between GPs and urologists regarding the early detection of PCa based on PSA testing in the northwest of Germany. The results of this study show that GPs and urologists differ on various aspects regarding PSA testing. In total, PSA testing was less accepted among GPs than among urologists. Further, differences in opinion on usefulness of the PSA test, in handling PSA results, consideration of guidelines in daily practice and knowledge about guidelines or actual study results on PSA testing were observed.

Our findings support earlier studies showing that variation in handling of PSA testing is due to, for example, insufficient knowledge or individual conviction of the doctor.[@CIT0019],[@CIT0027] Also the fact that a doctors' intention to screen himself for PCa using PSA testing predicted their tendency to screen their patients is supported by our results.[@CIT0028] Because it is known that the way the patient is informed about the PSA test has a high impact on the patient's satisfaction with early detection,[@CIT0016] this indirectly influences their satisfaction with the urological care. One study conducted in the United States found no difference between urologists and primary care physicians in the amount of PSA tests conducted.[@CIT0029] This is in contrast to our findings. Differences in health care systems and/or opinions on PSA testing might be an explanation for this.

The results also show that doctors have a different self-assessment than the study results show. All urologists indicated to know the S3 guideline in detail and 94.9% stated to consider the guideline in their daily practice, while the answers of some questions were not in consistence with the guideline. This is in accordance with other studies stating that although doctors have favorable attitudes toward guidelines on PCa, guideline knowledge is limited.[@CIT0030],[@CIT0031] One study stated that physicians handling after a normal or raised PSA seems to a large extent not in accordance with guidelines on PCa screening which agrees with our results.[@CIT0032]

The "dissenting opinion" of the 2014 version of the German S3 guideline says that men, not broaching early PCa screening by PSA testing to the doctor, should not be actively approached by the GP, while urologists are advised to proactively inform these men about PSA testing.[@CIT0015] This might explain some differences between GPs and urologists, but not all. Apart from this "dissenting opinion" regarding a more reserved approach for GPs, the recommendations in the guideline (eg, retesting after a raised PSA, etc.) are identical for doctors with different specialties. Further, the results show that urologists know the urological guidelines better than GPs. However, this might not fully explain the observed differences between them.

Accordingly, there seems to be an urgent need to educate and support doctors more (GPs, as well as urologists and doctors with other specialties dealing with PSA testing) concerning PSA testing.[@CIT0019],[@CIT0027],[@CIT0030] This is important for further improving the quality of the urological health care.

In the future, non-PSA-based effective screening tests for early detection of PCa based on urine analysis may be more acceptable to the GPs because of probably improved specificity. Current studies aim the development of such innovative diagnostic tools which may improve the characterization of the disease biology, allowing to determine whether the PCa will be aggressive or indolent, in order to avoid overtreatment.[@CIT0033] For example, urinary polyamines (eg, spermine) show potential to serve as novel PCa diagnostic biomarkers, which may be helpful to address the limited sensitivity and specificity problem of the serum PSA test.[@CIT0034]

Certain limitations must be considered. One limitation is the fact that the GPs who were invited belonged to the teaching network of the University of Oldenburg. It is conceivable that the doctors belonging to this network are more interested in science. This selection bias could lead to an underestimation of the results. Although none of the urologists surveyed is currently working at a hospital, the urologists, in general, could have a different attitude toward PSA testing than GPs and other physicians due to their earlier training in clinical oncologic sites. The low response proportions of 27.9% for the GPs and 13.2% for the urologists are another limitation. However, other studies among doctors like GPs and psychiatrists show comparable response proportions.[@CIT0035],[@CIT0036] A possible cause for this could be that physicians in Germany receive a lot of surveys, which partially are commercial and also well-paid. This survey was relatively extensive or time-consuming and without reimbursement. Thus, the participating physicians possibly had surpassing scientific interest and knowledge about clinical guidelines. As mentioned above, this circumstance may lead to selection bias.

Our pilot study provides an insight into the PSA tests conducted in the northwest of Germany. Till now, in Germany, only data from the German Health Interview and Examination Survey for Adults (2008--2011) are available, reporting that 30.6% of men aged 45 years or older had received a PSA test.[@CIT0037] In other countries, these data often are determined based on secondary data.[@CIT0038] As PSA testing is not an early detection service of the German statutory health insurance, these data are not gathered by the national health insurance.

If a patient wants a PSA test to be conducted, he has to pay the test by himself. The medical doctor "earns" a certain amount of money for every PSA test he or she conducts. Because financial incentives could affect doctors' treatment choices, this could be a motivation for a doctor to conduct a PSA test.[@CIT0039],[@CIT0040] Our results also showed that 50.0% of the urologists analyzed the blood samples in their own practice. This could be an extra motivational factor for doctors to stimulate men to conduct a PSA test. To determine the influence of financial factors on conducting a PSA test further research is needed.

Conclusion {#S0005}
==========

This pilot study argues for differences in various aspects regarding PSA testing between GPs and urologists, wherein a low response rate represents a limitation in some respects. Physicians with surpassing scientific interest are probably over-represented, which may lead to selection bias. There is an urgent need to educate and support doctors more on topics related to PSA testing. This is important for further improving the quality of urological health care. Therefore, the interdisciplinary exchange needs to be continued and extended to achieve a consistent level of knowledge among doctors with different specialties.

To validate the results of this study and to constitute the consequences of the different information levels on the urological care, a follow-up project is planned. This project will be conducted in different regions in Germany and will include GPs as well as practicing urologists and those working at hospitals. Further, a survey among men aged \>45 years is planned to assess the satisfaction with the urological health care in Germany.
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Table S1Questions on PSA testing V by general practitioners and urologists, n (%)QuestionGPsUrologistsNeverRarelySometimesOftenAlwaysNeverRarelySometimesOftenAlways**On which occasions do you inform your patient on PSA testing?Within an early cancer detection examination**7.3 (3)7.3 (3)9.8 (4)19.5 (8)56.1 (23)0 (0.0)0 (0.0)0 (0.0)1 (7.1)13 (92.9)**In case of a positive family anamnesis**4 (9.8)2 (4.9)4 (9.8)9 (22.0)22 (53.7)0 (0.0)0 (0.0)1 (7.1)0 (0.0)13 (92.9)**In case of discomfort in the lower urinary tract**7 (17.1)9 (22.0)8 (19.5)8 (19.5)9 (22.0)0 (0.0)1 (7.1)2 (14.3)8 (57.1)3 (21.4)**In case of unclear discomfort**5 (12.2)12 (29.3)10 (24.4)10 (24.4)4 (9.8)0 (0.0)1 (7.1)3 (21.4)7 (50.0)3 (21.4)**How often do you discuss the following aspects with your patients before performing a PSA test?Impact on overall mortality**7 (17.1)7 (17.1)4 (9.8)9 (22.0)14 (34.1)1 (7.1)1 (7.1)3 (21.4)5 (35.6)4 (28.6)**Impact on disease-specific mortality**3 (7.3)4 (9.8)3 (7.3)14 (34.1)17 (41.5)1 (7.1)1 (7.1)1 (7.1)6 (42.9)5 (35.7)**Impact on risk of metastasis**5 (12.2)4 (9.8)8 (19.5)9 (22.0)15 (36.6)0 (0.0)1 (7.1)1 (7.1)9 (64.3)3 (21.4)**Potential overdiagnosis**1 (2.4)2 (4.9)5 (12.2)10 (24.4)23 (56.1)1 (7.1)1 (7.1)1 (7.1)5 (35.7)6 (42.9)**Issue of false positives**0 (0.0)0 (0.0)6 (14.6)12 (29.3)23 (56.1)0 (0.0)0 (0.0)0 (0.0)4 (28.6)10 (71.4)**Potential anxiety during waiting on test result**6 (14.6)7 (17.1)6 (14.6)7 (17.1)15 (36.6)2 (14.3)4 (28.6)1 (7.1)6 (42.9)1 (7.1)**Potential follow-up examinations if the test result is conspicuous**1 (2.4)0 (0.0)8 (19.5)11 (26.8)21 (51.2)0 (0.0)0 (0.0)1 (7.1)3 (21.4)10 (71.4)**Adverse effects of the treatment**1 (2.4)4 (9.8)12 (29.3)11 (26.8)13 (31.7)0.0 (0)0.0 (0)6 (42.9)5 (35.7)3 (21.4)[^12] Table S2Questions on digital rectal examining by general practitioners and urologists, n (%)QuestionGPsUrologistsNeverRarelySometimesOftenAlwaysNeverRarelySometimesOftenAlways**How often do you examine digito rectally in the following situations?During an early cancer detection examination**0 (0.0)0 (0.0)4 (9.8)4 (9.8)33 (80.5)0 (0.0)0 (0.0)0 (0.0)2 (14.3)12 (85.7)**If there is blood in the patient´s stool**0 (0.0)0 (0.0)3 (7.3)13 (31.7)25 (61.0)0 (0.0)0 (0.0)0 (0.0)3 (21.4)11 (78.6)**If the patient has a voiding disorder**1 (2.4)3 (7.3)17 (41.5)12 (29.3)8 (19.5)0 (0.0)0 (0.0)0 (0.0)4 (28.6)10 (71.4)**If the patient is asymptomatic**17 (41.5)12 (29.3)8 (19.5)4 (9.8)0 (0.0)0 (0.0)0 (0.0)4 (28.6)6 (42.9)4 (28.6)[^13]

[^1]: **Abbreviation:** GPs, general practitioners.

[^2]: **Abbreviations:** AOK, Allgemeine Ortskrankenkasse, one of the German statutory health insurances; GPs, general practitioners; PSA, prostate-specific antigen.

[^3]: **Abbreviations:** GPs, general practitioners; PSA, prostate-specific antigen.

[^4]: **Abbreviations:** GPs, general practitioners; PSA, prostate-specific antigen.

[^5]: **Abbreviations:** GPs, general practitioners; PSA, prostate-specific antigen; n/a, not applicable.

[^6]: **Abbreviations:** GPs, general practitioners; PSA, prostate-specific antigen.

[^7]: **Abbreviations:** ACS, American Cancer Society; AUA, American Urological Association; EAU, European Association of Urology; DEGAM, German College of General Practice and Family Medicine; ERSPC, European Randomized Study of Screening for Prostate Cancer; GPs, general practitioners; PLCO, Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; PSA, prostate-specific antigen; NCCN, National Comprehensive Cancer Network; USPSTF, United States Preventive Services Task Force.

[^8]: **Abbreviations:** ACS, American Cancer Society; AUA, American Urological Association; EAU, European Association of Urology; DEGAM, German College of General Practice and Family Medicine; ERSPC, European Randomized Study of Screening for Prostate Cancer; GPs, general practitioners; PLCO, Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; PSA, prostate-specific antigen; NCCN, National Comprehensive Cancer Network; USPSTF, United States Preventive Services Task Force.

[^9]: **Abbreviations:** GPs, general practitioners; PSA, prostate-specific antigen.

[^10]: **Abbreviation:** GPs, general practitioners.

[^11]: **Abbreviations:** BPH, benign prostatic hyperplasia; GPs, general practitioners; PCa, prostate cancer, PSA, prostate-specific antigen.

[^12]: **Abbreviations:** GPs, general practitioners; PSA, prostate-specific antigen.

[^13]: **Abbreviation:** GPs, general practitioners.
